TNON Tenon Medical (TNON) Insider Trading, Ownership & Congress Trades
Medical Devices · Surgical & medical instruments & apparatus · CIK 0001560293
SEC filings
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
7
13F, latest reported quarter
Conversions, 180 days
9
Codes C/M, not in net · $0 priced
What the filings say about TNON
Insiders, 180 days
-$105.4K net sold
1 buyer · 1 seller · 0% of sales under a 10b5-1 plan
Tenon Medical insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Tenon Medical, Inc. insiders sold a net $105.4K of stock across 24 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 14 earlier Form 4 trades (code P or S) here by this insider (6 buys, 8 sales), the last on Sep 9, 2026.
- The trade is 197.2% of the 15,839 shares held after it.
- No other insider bought within 30 days.
- 7 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider HRT FINANCIAL LP bought about $91.2K of TNON on Sep 10, 2026; 7 funds added in the latest 13F quarter.Context
- 14 earlier Form 4 trades (code P or S) here by this insider (6 buys, 8 sales), the last on Sep 9, 2026.
- The trade is 178.5% of the 15,839 shares held after it.
- No other insider bought within 30 days.
- 7 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider HRT FINANCIAL LP bought about $113.6K of TNON on Sep 10, 2026; 7 funds added in the latest 13F quarter.Context
- 14 earlier Form 4 trades (code P or S) here by this insider (6 buys, 8 sales), the last on Sep 9, 2026.
- The trade is 53.2% of the 15,839 shares held after it.
- No other insider bought within 30 days.
- 7 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider HRT FINANCIAL LP bought about $41.5K of TNON on Sep 10, 2026; 7 funds added in the latest 13F quarter.Context
- 14 earlier Form 4 trades (code P or S) here by this insider (6 buys, 8 sales), the last on Sep 9, 2026.
- The trade is 414.1% of the 15,839 shares held after it.
- No other insider sold within 30 days.
- 7 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider HRT FINANCIAL LP sold about $364.6K of TNON on Sep 10, 2026, the largest insider sale at the company on our record; 7 funds added in the latest 13F quarter.Context
- 11 earlier Form 4 trades (code P or S) here by this insider (5 buys, 6 sales), the last on Sep 8, 2026.
- The trade is 277.2% of the 18,182 shares held after it.
- No other insider sold within 30 days.
- 7 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider HRT FINANCIAL LP sold about $131.5K of TNON on Sep 9, 2026, the largest insider sale at the company on our record; 7 funds added in the latest 13F quarter.24 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$105.4K over 180 days
-$105.4K over 90 days · -$105.4K of it by a 10%+ holder
more than 55% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
7 funds bought in last quarter
below 92% of Medical Devices
Revenue
+20.4% year over year
more than 74% of Medical Devices
Margin
-318.4% net margin
below 89% of Medical Devices
Buybacks
no share repurchases reported
Short interest
8.4% of the float short (float per yahoo 2026-10-27) · 1.0 days to cover · settled 2026-10-15
more than 79% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch TNON
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+82.9%12M
Insider buyInsider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns TNON: institutional holders (13F)
13F holdings, latest reported quarter
430,407 sh
$140.4K
194,355 sh
$56.4K
4,720,000 sh
$51.0K
80,566 sh
$26.3K
71,715 sh
$23.4K
Congress trades in TNON
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
TNON planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
TNON mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Extended Market Index Fund
$89.5K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$23.4K position · as of 2026-06-30
0.0%
Fidelity Series Total Market Index Fund
$8.3K position · as of 2026-05-31
0.0%
Fidelity Nasdaq Composite Index Fund
$440 position · as of 2026-05-31
0.0%
Blackstone Alternative Multi-Strategy Fund
$11 position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $105.4K sold by insiders over 180 days, 7 funds added last quarter. Each figure is a federal filing, dated the day it went public.
TNON financials
Revenue growth
+20.4%
XBRL, annual
Net margin
-318.4%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$5.3M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM TNON
| FY Dec 2025 | $3.9M |
| FY Dec 2024 | $3.3M |
| FY Dec 2023 | $2.9M |
| FY Dec 2022 | $691.0K |
| FY Dec 2021 | $160.0K |
| Jun 2026 | $1.3M |
| Mar 2026 | $1.4M |
| Dec 2025 | $1.5M |
| Sep 2025 | $1.2M |
| Jun 2025 | $564.0K |
| Mar 2025 | $726.0K |
| Dec 2024 | $770.0K |
| Sep 2024 | $887.0K |
At each fiscal year end
Single quarter
Net margin, TTM
-257.9%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM TNON
| FY Dec 2025 | -318.4% |
| FY Dec 2024 | -417.2% |
| FY Dec 2023 | -532.1% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -316.7% |
| Mar 2026 | -252.1% |
| Dec 2025 | -191.2% |
| Sep 2025 | -284.7% |
| Jun 2025 | -491.0% |
| Mar 2025 | -498.1% |
| Dec 2024 | -400.9% |
| Sep 2024 | -359.0% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$12.1M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM TNON
| FY Dec 2025 | n/a |
| FY Dec 2024 | -$10.1M |
| FY Dec 2023 | -$12.5M |
| FY Dec 2022 | -$12.9M |
| FY Dec 2021 | -$4.4M |
| Jun 2026 | -$2.9M |
| Mar 2026 | -$3.0M |
| Dec 2025 | -$2.4M |
| Sep 2025 | -$3.7M |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | -$2.7M |
| Sep 2024 | -$2.4M |
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
Debt to equity TNON
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
Cash flow to debt TNON
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-551.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity TNON
| FY Dec 2025 | -228.1% |
| FY Dec 2024 | -405.2% |
| FY Dec 2023 | -443.3% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -551.2% |
| Mar 2026 | -220.3% |
| Dec 2025 | -228.1% |
| Sep 2025 | -197.3% |
| Jun 2025 | -335.5% |
| Mar 2025 | -211.0% |
| Dec 2024 | -405.2% |
| Sep 2024 | -256.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-130.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets TNON
| FY Dec 2025 | -121.9% |
| FY Dec 2024 | -168.9% |
| FY Dec 2023 | -178.7% |
| FY Dec 2022 | -185.8% |
| FY Dec 2021 | -76.0% |
| Jun 2026 | -130.2% |
| Mar 2026 | -94.7% |
| Dec 2025 | -121.9% |
| Sep 2025 | -109.5% |
| Jun 2025 | -147.9% |
| Mar 2025 | -128.1% |
| Dec 2024 | -168.9% |
| Sep 2024 | -134.8% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital TNON
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-253.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed TNON
| FY Dec 2025 | -164.8% |
| FY Dec 2024 | -246.3% |
| FY Dec 2023 | -267.4% |
| FY Dec 2022 | -1,465% |
| FY Dec 2021 | n/a |
| Jun 2026 | -253.6% |
| Mar 2026 | -149.1% |
| Dec 2025 | -164.8% |
| Sep 2025 | -152.4% |
| Jun 2025 | -231.7% |
| Mar 2025 | -164.4% |
| Dec 2024 | -246.3% |
| Sep 2024 | -194.9% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing TNON
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no debt line filed
Enterprise value TNON
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-845.9%
TTM free cash flow over market value at close 2026-10-27
FCF yield TNON
| FY Dec 2025 | n/a |
| FY Dec 2024 | -170.7% |
| FY Dec 2023 | -40.2% |
| FY Dec 2022 | -0.9% |
| FY Dec 2021 | n/a |
| Jun 2026 | -320.0% |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | -134.9% |
| Mar 2025 | -86.6% |
| Dec 2024 | -170.7% |
| Sep 2024 | -57.9% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing TNON
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $3.9M | $3.3M | $2.9M | $691.0K |
| Gross profit | $2.4M | $1.7M | $1.2M | -$641.0K |
| Operating income | -$12.8M | -$13.8M | -$15.7M | -$18.7M |
| Net income | -$12.6M | -$13.7M | -$15.6M | -$18.9M |
| EPS (diluted) | -1.70 | -11.26 | -68.64 | -23.62 |
| Operating cash flow | -$10.7M | -$9.9M | -$12.2M | -$12.0M |
| Cash | $3.8M | $6.5M | $2.4M | $2.1M |
SEC XBRL, fiscal years, as known on 2026-10-28
TNON Stock Sonar score 5/7 axes
Find similar shapesCompareTNON ranks highest on growth (74th percentile) and insider conviction (52nd), and lowest on institutional and government (8th), among Medical Devices peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
TNON filings, in plain words
Are Tenon Medical insiders buying or selling TNON?
In the 180 days to 2026-10-28, Tenon Medical insiders were net sellers, a net $105.4K: $500.2K of purchases and $605.7K of sales reported on Form 4, by 1 buyer and 1 seller.
Read the full summary
In the 180 days to 2026-10-28, Tenon Medical insiders were net sellers of TNON, a net $105.4K across purchases and sales reported on Form 4 by 1 buyer and 1 seller. Most of that figure, $105.4K, came from a holder of 10% or more rather than an officer or director. None of the 9 insider sales was flagged as made under a Rule 10b5-1 plan. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
